been approved by the Director of the Centers for Disease Control and Prevention and appear on CDC immunization schedules must be covered by applicable health plans.

**Matters To Be Considered:** The agenda will include discussions on cholera vaccine, hepatitis B vaccine, influenza vaccine, zoster vaccine, orthopoxivirus vaccine, pneumococcal vaccine, rabies vaccine and tickborne encephalitis vaccine. A recommendation vote on the rabies vaccine is scheduled. Agenda items are subject to change as priorities dictate. For more information on the meeting agenda visit [https://www.cdc.gov/vaccines/acip/meetings/meetings-info.html](https://www.cdc.gov/vaccines/acip/meetings/meetings-info.html).

**Meeting Information:** The meeting will be webcast live via the World Wide Web; for more information on ACIP please visit the ACIP website: [http://www.cdc.gov/vaccines/acip/index.html](http://www.cdc.gov/vaccines/acip/index.html).

**Public Participation**

Interested persons or organizations are invited to participate by submitting written views, recommendations, and data. Please note that comments received, including attachments and other supporting materials are part of the public record and are subject to public disclosure. Do not include any information in your comment or supporting materials that you consider confidential or inappropriate for public disclosure. If you include your name, contact information, or other information that identifies you in the body of your comments, that information will be on public display. CDC will review all submissions and may choose to redact, or withhold, submissions containing private or confidential or inappropriate for public disclosure. If you include your name, contact information, or other information that identifies you in the body of your comments, that information will be on public display. CDC will review all submissions and may choose to redact, or withhold, submissions containing private or confidential or inappropriate for public disclosure. If you include your name, contact information, or other information that identifies you in the body of your comments, that information will be on public display. CDC does not accept comment by email. Written Public Comment: Written comments must be received on or before February 25, 2021. Oral Public Comment: This meeting will include time for members of the public to make an oral comment. Oral public comment will occur before any scheduled votes including all votes relevant to the ACIP’s Affordable Care Act and Vaccines for Children Program roles. Priority will be given to individuals who submit a request to make an oral public comment before the meeting according to the procedures below. Procedure for Oral Public Comment: All persons interested in making an oral public comment at the February 24, 2021 ACIP meeting must submit a request at [http://www.cdc.gov/vaccines/acip/meetings/](http://www.cdc.gov/vaccines/acip/meetings/) no later than 11:59 p.m., EST, February 18, 2021 according to the instructions provided.

If the number of persons requesting to speak is greater than can be reasonably accommodated during the scheduled time, CDC will conduct a lottery to determine the speakers for the scheduled public comment session. CDC staff will notify individuals regarding their request to speak by email by February 19, 2021. To accommodate the significant interest in participation in the oral public comment session of ACIP meetings, each speaker will be limited to 3 minutes, and each speaker may only speak once per meeting.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh, Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

**FOR FURTHER INFORMATION CONTACT:** Koo-Whang Chung, M.P.H., HICPAC, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, CDC, 1600 Clifton Road NE, Mailstop H16–3, Atlanta, Georgia 30329–4027, Telephone: (404) 498–0730, Email: HICPAC@cdc.gov.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh, Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**National Center for Health Statistics (NCHS), ICD–10 Coordination and Maintenance (C&M) Committee Meeting**

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of meeting.

**SUMMARY:** The CDC, National Center for Health Statistics (NCHS), Classifications and Public Health Data Standards Staff, announces the following meeting of the ICD–10 Coordination and Maintenance (C&M) Committee meeting. This meeting is open to the public, limited only by audio lines available. Online Registration is not required.

**DATES:** The meeting will be held on March 9, 2021, from 9:00 a.m. to 5:00 p.m., EDT, and March 10, 2021, from 9:00 a.m. to 5:00 p.m., EDT.

**ADDRESSES:** This is a virtual meeting. Information will be provided on each of our respective web pages when it becomes available. For CDC/NCHS [https://www.cdc.gov/nchs/icd/icd10cm Maintenance.htm](https://www.cdc.gov/nchs/icd/icd10cm Maintenance.htm). For CMS [https://www.cms.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/meetings](https://www.cms.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/meetings).

**FOR FURTHER INFORMATION CONTACT:** Traci Ramirez, Program Specialist, CDC, 3311 Toledo Road, Hyattsville, Maryland 20782, Telephone (301) 458–4454; TRamirez@cdc.gov.

**SUPPLEMENTARY INFORMATION:**

**Purpose:** The ICD–10 Coordination and Maintenance (C&M) Committee is a public forum for the presentation of proposed modifications to the International Classification of Diseases, Tenth Revision, Clinical Modification and ICD–10 Procedure Coding System.
Matters To Be Considered: The tentative agenda will include discussions on ICD–10–CM and ICD–10–PCS topics listed below. Agenda items are subject to change as priorities dictate. Please refer to the posted agenda for updates one month prior to the meeting.

ICD–10–PCS Topics

1. Administration of Trilaciclib *
2. Administration of ZEPZELCA™ (lurbinectedin) *
3. Administration of ENSPRYNG™ (satralizumab-mwge) *
4. Administration of ciltacabtagene autoleucel (cilta-cel) *
5. Administration of Amivantamab *
6. Administration of Molnupiravir *
7. Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (PRFCG) *
8. Administration of OTL–103
9. Administration of OTL–200
10. Application of Topical Agent for Non-Excisional Eschar Removal *
11. Application of Bioengineered Skin Construct *
12. Computer-Aided Assessment, Characterization and Notification Software for CT Scan *
13. Computer-Aided Detection, Triage and Notification Software for Acute Subdural Hemorrhage with Non-Contrast CT of the Head *
14. Computer-Aided Detection, Triage and Notification Software for Computed Tomography Pulmonary Angiography (CTPA) *
15. Computer-Aided Detection, Triage and Notification Software for Stroke with Non-Contrast CT of the Head *
16. Transhilar thoracic echocardiography with AI-Guide Image Acquisition *
17. Tissue Oxygen Saturation Imaging of GI Tract *
18. Mechanical Thrombectomy using AI Assistance *
19. Transcatheter Replacement of Pulmonary Valve *
20. Combined Thoracic Aortic Arch Replacement and Descending Thoracic Aorta Restricion *
21. Extraluminal Autologous Saphenous Vein Graft Support *
22. Coronary Intravascular Lithotripsy (IVL) *
23. Percutaneous Creation of an Arterio-Venous Fistula (AVF) *
24. Pharyngeal Electrical Stimulation *
25. Patient Specific Intervertebral Body Fusion *
26. Colonic Irrigation for Colonoscopy *
27. Blood Collection Utilizing Specimen Collection Diversion *
28. Concurrent Measurement of mRNA, PCR test and Detection of Antibodies *
29. Metal Ureteral Stents
30. Regional Anticoagulation for Renal Replacement Therapy
31. Gene Expression Assay
32. Total Artificial Heart Systems
33. Tourniquets Used for Acute Hemorrhage Control
34. Measurement of Flow in a Cerebral Fluid Shunt
35. Endoscopic Suturing Device for Upper and Lower GI Procedures
36. Section X Updates
37. Addenda and Key Updates

* Applicant has submitted a New Technology Add-on Payment (NTAP) application for FY 2022.

Presentations for procedure code requests are conducted by both the requestor and CMS during the Coordination & Maintenance Committee meeting. Discussion from the requestor generally focuses on the clinical issues for the procedure or technology, followed by the proposed coding options from a CMS analyst. Topics presented may also include requests for new procedure codes that relate to a new technology add-on payment (NTAP) policy request.

CMS is modifying the approach for presenting the new technology add-on payment (NTAP) related ICD–10–PCS procedure code requests that involve the administration of a therapeutic agent for the March 9–10, 2021 ICD–10 Coordination and Maintenance Committee meeting due to the volume of NTAP applications and corresponding procedure code requests being considered for FY 2022. Consistent with the requirements of section 1886(d)(5)(K)(iii) of the Social Security Act, applicants submitted requests to create a unique procedure code to describe the administration of a therapeutic agent, such as the option to create a new code in Section X within the ICD–10–PCS procedure code classification. In order to accommodate the number of requests received for the March 9–10, 2021 ICD–10 Coordination and Maintenance Committee meeting, CMS will initially only display those meeting materials associated with the NTAP related ICD–10–PCS procedure code requests that involve the administration of a therapeutic agent on the CMS website in early February 2021 at: https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials. Any inquiries related to the procedure code topics scheduled for the March 9–10, 2021 ICD–10 Coordination and Maintenance Committee meeting that are under consideration for October 1, 2021 implementation should be sent to the CMS mailbox at: ICDProcedureCodeRequest@cms.hhs.gov.

ICD–10–CM Topics

1. Anatomical Flank Specificity
2. ANCA vasculitis
3. Amenorrhea related conditions of Newborn
4. Atrial and Atrioventricular Septal Defect
5. Alzheimer’s/Vascular Dementia
6. Endometriosis
7. Limb girdle muscular dystrophies expansion
8. Lumbar disc degeneration, with pain
9. Mild Cognitive Disorder due to Physiological Conditions (representation)
10. Prolonged Grief Disorder
11. Refractory Angina Pectoris
12. Rheumatic mitral valve leaflet calcification
13. Slipped Upper Femoral Epiphysis
14. Short Stature due to Endocrine Disorder
15. Substance Use Disorder, unspecified, in remission
16. Torsade de pointes expansion
17. Von Willebrand Disease

CMS will solicit public comments regarding any clinical questions or coding options included for these six procedure code topics in advance of the meeting continuing through the end of the public comment period, April 9, 2021. Members of the public should send any questions or comments to the CMS mailbox at: ICDProcedureCodeRequest@cms.hhs.gov by the April 9, 2021 deadline.
18. Addenda

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2021–01740 Filed 1–26–21; 8:45 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552(b)(c)(4) and 552(b)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Biology of Development and Aging Integrated Review Group; Radiation Therapeutics and Biology Study Section.


Time: 10:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Malaya Chatterjee, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6192, MSC 7804, Bethesda, MD 20892, 301–806–2515, chatterm@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Molecular Genetics A.

Date: February 22, 2021.

Time: 1:00 p.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Elena Smirnova, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5187, MSC 7840, Bethesda, MD 20892, 301–357–9112, smirnov@csr.nih.gov.

Name of Committee: Interdisciplinary Molecular Sciences and Training Integrated Review Group; Cellular and Molecular Technologies Study Section.

Date: February 24–25, 2021.

Time: 9:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Tatiana V. Cohen, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5213, Bethesda, MD 20892, 301–455–2364, tatiana.cohen@nih.gov.

Name of Committee: Cardiovascular and Respiratory Sciences Integrated Review Group; Integrative Myocardial Physiology/Pathophysiology A Study Section.

Date: February 24–25, 2021.

Time: 9:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Abdelouahab Aitouche, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4222, MSC 7814, Bethesda, MD 20892, 301–435–2365, aitouchea@csr.nih.gov.

Name of Committee: Population Sciences and Epidemiology Integrated Review Group; Neurological, Aging and Musculoskeletal Epidemiology Study Section.

Date: February 24–25, 2021.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Heidi B. Friedman, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1012A, MSC 7770, Bethesda, MD 20892, 301–435–1721, hfriedman@csr.nih.gov.

Name of Committee: Integrative, Functional and Cognitive Neuroscience Integrated Review Group; Neurobiology of Pain and itch Study Section.

Date: February 24–25, 2021.

Time: 10:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: M. Catherine Bennett, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5182, MSC 7846, Bethesda, MD 20892, 301–435–1766, bennettc3@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR Panel: Understanding Alzheimer’s Disease.

Date: February 24, 2021.

Time: 10:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Boris P. Sokolov, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5217A, MSC 7846, Bethesda, MD 20892, 301–408–9115, bsokolov@csr.nih.gov.

Name of Committee: Molecular, Cellular and Developmental Neurosciences Integrated Review Group; Neurodifferentiation, Plasticity, Regeneration and Rhythmicity Study Section.

Date: February 24–25, 2021.

Time: 11:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Joanne T. Fujii, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4184, MSC 7850, Bethesda, MD 20892, 301–435–1178, fujiji@csr.nih.gov.


David W. Freeman,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2021–01733 Filed 1–26–21; 8:45 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a